Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases

Several large clinical trials have shown renal and cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated. There have been accumulating studies which report that SGLT2 inhibitors ameliorate autophagy def...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Kazuhiko, Kitamura, Shinji, Tsuji, Kenji, Wada, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566701/
https://www.ncbi.nlm.nih.gov/pubmed/34744742
http://dx.doi.org/10.3389/fphar.2021.761842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566701/
https://www.ncbi.nlm.nih.gov/pubmed/34744742
http://dx.doi.org/10.3389/fphar.2021.761842

Ejemplares similares